Gilead pads out its antiviral portfolio with more acquisitions - The Pharma Letter

Gilead pads out its antiviral portfolio with more acquisitions  The Pharma Letter

Gilead Sciences (Nasdaq: GILD) today announced today that it has licensed three pre-clinical antiviral programs, including investigational agents with the ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more